Great Bay Bio Showcases AI-Driven Drug Development Platforms at BIONNOVA Shanghai and Merck Shenzhen Forums, CEO Dr. Chen Liang Unveils Commercialization Strategy

Recently, Great Bay Bio (GBB) successively attended two major industry events: the 7th BIONNOVA Biomedical Innovators Forum & Exhibition (Zhangjiang Science Hall, Shanghai) and the Merck 2026 Antibody Drug Development Process Innovation Forum (Shenzhen). Through keynote speeches, brand exhibitions, and one-on-one in-depth business discussions, the company focused on the pain points of biopharmaceutical industry development, discussed cutting-edge trends and process innovations in life sciences, and deepened ecosystem cooperation.Dr. Liang Chen, Co-founder and CEO of Great Bay Bio, Delivered a Keynote Speech at the Zhangjiang Forum in Shanghai, Sharing the Company’s Practical Achievements in Driving AI-Driven Drug Development from Conceptual Research to Commercial Implementation, Tearing Away the "Emperor's New Clothes" of AI in Pharmaceuticals, and Assisting Clients in Accelerating Their Products Towards Engineering and Commercialization.

▲GBB Co-founder and CEO Dr. Liang Chen Delivers Keynote Speech

At the Shanghai Forum, Dr. Chen Liang introduced several commercial intelligent technology platforms implemented by Great Bay Bio, relying on cutting-edge technologies such as AI and site-specific integration, as well as the PCC Prime system.Providing new technical pathways and integrated solutions for industrial development. Innovation highlights include: intelligent targeted integration of cells to solve complex molecular development challenges, revolutionary elimination of the cell pool construction step, intelligent prediction of molecular sequences with simultaneous optimization of molecular affinity, humanization, and drug-likeness. Great Bay Bio achieves PCC in 8 months, helping customers accelerate product development while minimizing product development risks.

▲Shanghai Forum Speech Venue

Dr. Chen Liang focused on explaining how Great Bay Bio (GBB) tears the "Emperor's New Clothes" of AI pharmaceuticals, pushing AI pharmaceuticals from conceptual research towards a commercially viable closed loop:AI Drug Discovery is a System Engineering of Multi-Model Collaboration + Experimental Closed-Loop: A Single Model's Impressive Performance Does Not Equal End-to-End Commercial Success. The Core Bottleneck of the Current Pipeline Lies in the Accumulation of Systematic Errors in the Translation Phase. Therefore, Great Bay Bio (GBB) Breaks Away from the Internal Competition of Single Models, Building a System-Level Decision Framework Through Multi-Model Collaboration, Feasibility Pre-Screening, and Experimental Feedback Closed-Loop, Leading the Future of AI Drug Discovery.

▲GBB Tears the "Emperor's New Clothes" of AI Drug Development

At the Shenzhen Forum, Great Bay Bio, as a long-term strategic partner of Merck, has achieved deep synergy with Merck in areas such as cell line resources and process development, strengthening the supply chain and technical foundation for biopharmaceutical R&D and production.GBB Team Engages in In-depth Exchange with Industry Experts and R&D Peers, Focusing on Core Issues Such as Antibody Drug Process Optimization, Quality System Control, and Scale Production Amplification, Sharing a Mature and Comprehensive CMC Overall Solution to Efficiently Overcome Various R&D Bottlenecks in Bioprocess Development, Collaboratively Building a Stable, Efficient, and Low-cost Large Molecule Drug R&D Industrial Chain.

▲Shenzhen Merck Forum Scene

Riding the wave of high-quality development in the biopharmaceutical industry, Great Bay Bio has been using AI and site-specific integration core technologies as its engine to continuously build differentiated, highly implementable professional service capabilities.In the future, the company will further deepen strategic cooperation with industry leaders such as Merck, broaden industrial exchange channels at home and abroad, accelerate the domestic and international industrialization process, while collaborating with upstream and downstream partners in the industry chain to innovate. It will empower the quality enhancement and upgrading of China's large molecule biopharmaceuticals industry, and help Chinese innovative pharmaceutical companies achieve technological breakthroughs and deep international layouts in the global biomedicine track.